Objectives: To investigate the effects of increasing Mg intakes, above the usual dietary intake, on blood pressure and on biomarkers of bone metabolism in healthy young adult females. Design: A double-blind, placebo-controlled, randomised crossover Mg intervention trial. Setting: The study was conducted in the Department of Nutrition, University College, Cork, Ireland. Subjects: Twenty-six healthy (normotensive) adult females aged 20 ± 28 y were recruited from University College, Cork. Intervention: Subjects were randomly assigned to their self-selected diets ( $ 11 mmol Mgad) or their selfselected diet with a 10 mmolad Mg supplement as Mg(OH) 2 ( $ 22 mmol Mgad) for 28 d followed by cross-over to the alternative diet for a further 28 d. During each dietary period urines (last 3 d) and blood (morning of 27 d) were collected and blood pressure was measured on the morning of 28 d. Results: Increasing Mg intake from the usual level (11 mmolad) to 22 mmolad for 28 d increased urinary excretion of Mg by 36% and erythrocyte Mg content by 5% but had no effect on serum Mg, Ca, PTH, osteocalcin or bone-speci®c alkaline phosphatase (biomarkers of bone formation), urinary pyridinium crosslinks of collagen (biomarkers of bone resorption), or on blood pressure. Conclusion: Increasing the mean Mg intake in healthy young adult females above the usual dietary intake, which is currently above the US EAR (estimated average requirement), but below the US RDA for Mg, does not affect blood pressure or the rate of bone turnover. Sponsorship: Funding from the Department of Agriculture and Food, Dublin.
Introduction
Recent reports have recommended dietary Mg intakes which are higher than previously proposed. The US Food and Nutrition Board has recently reviewed the data on metabolic balance for Mg and has revised upwardly the recommended daily allowance (RDA) (310 mg (12.8 mmol)ad and 400 mg (16.5 mmol)ad for adult females and males (aged 19 ± 30 y), respectively) (Institute of Medicine, 1997) . Similarly, Durlach & Mareschi (1991) proposed that 6 mg (0.2 mmol)akg body weight per day (that is, 330 mg (13.6 mmol)ad and 420 mg (17.3 mmol)ad for a 55 kg woman and 70 kg male, respectively) is the minimum Mg required to maintain metabolic balance in equilibrium in European countries. There is evidence that many young adults, especially women, in various European countries and in the US fail to achieve these recommended intakes of Mg (Gregory et al, 1990; Van Dokkum, 1995; Cleveland et al, 1996 ; Institute of Medicine, 1997) and this raises the issue of possible adverse effects of lower than recommended intakes.
Mg plays important roles in regulating blood pressure and in bone growth and metabolism (Institute of Medicine, 1997; Rude, 1998) . A number of epidemiological studies have demonstrated a relationship between low dietary intake of Mg and increased blood pressure (Joffres et al, 1987; Witteman et al, 1989; Ascherio et al, 1992; Ma et al, 1995) . However, intervention studies with Mg therapy in hypertensives and normotensives have led to con¯icting results. Several studies in hypertensives and normotensives have shown a blood pressure lowering effect of Mg supplements (in hypertensives, Dyckner & Wester, 1983; Saito et al, 1988; Motoyama et al, 1989; Geleijnse et al, 1994; Witteman et al, 1994; in normotensives, Itoh et al, 1997) , while others have not (in hypertensives, Cohen et al, 1984; Cappuccio et al, 1985; Henderson et al, 1986; Zemel et al, 1990; Durlach et al, 1992; Haga, 1992; Kisters et al, 1993; Plum-Wirell et al, 1994; Sacks et al, 1995; in normotensives, Haga, 1992; Yamamote et al, 1995; Sacks et al, 1998) . Therefore, the effect of oral Mg supplementation on blood pressure remains controversial and especially, in normotensives where data is limited.
Experimental Mg de®ciency in the rat has been reported to result in decreased bone growth and bone volume, and increased bone resorption and skeletal fragility (Kenney et al, 1994; Rude, 1998) . A number of studies have reported signi®cant reductions in serum Mg and bone Mg content in postmenopausal women with osteoporosis (Manicourt et al, 1981; Cohen, 1988; Reginster et al, 1989; Cohen & Laor, 1990; Stendig-Lindberg et al, 1993) . However, epidemiological studies relating Mg intake to bone mass or rate of bone loss have been con¯icting (Yano et al, 1985; Fruedenheim et al, 1986; Angus et al, 1988; Tucker et al, 1995) . Furthermore, only one study of the effect of Mg supplementation on bone mass is available. Stendig-Lindberg et al (1993) reported an increase in radial bone mass in 31 osteoporotic postmenopausal women after 1 y of dietary Mg supplements (750 mg (30.9 mmol)ad for the ®rst six months followed by 250 mg (10.3 mmol)ad). Dimai et al (1998) have recently shown that daily supplementation of the usual diet of 12 healthy young adult males with 15 mmol Mg for 30 d reduced serum levels of osteocalcin and procollagen peptide (markers of bone formation) and serum type I collagen telopeptide (a marker of bone resorption) suggesting that Mg supplementation may suppress the rate of bone turnover in healthy non-Mg-de®cient individuals. However, this study had relatively low numbers and was not of a randomised crossover design.
Therefore, the objectives of this study were to investigate the effects of increasing Mg intakes, above the usual dietary intake, on blood pressure and on biomarkers of bone metabolism in healthy young adult females over a 28 d period using a double-blind, placebo-controlled, randomised crossover study design.
Methods

Subjects
Twenty-six young healthy adult females (mean age 23.0 (range 20 ± 28) y) were recruited from among a group of postgraduates at University College, Cork. The mean height, weight and body mass index (BMI) for the subjects are provided in Table 1 . The subjects were normotensives (World Health Organisation (WHO) criteria`140 mm Hg for systolic andaor`85 mm Hg for diastolic blood pressure), without any history of bone or articular disease, and with no intake of medicine that could affect bone or cartilage metabolism. Additional exclusion criteria included chronic illness or taking nutritional supplements. Subjects were requested to avoid vigorous exercise and excessive alcohol intake for the duration of the study.
Ethical considerations
Before participation in this study, all subjects signed an informed consent document approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals.
Design
The study consisted of a double-blind, placebo-controlled, randomised crossover trial of the effect of Mg supplementation of the usual diet (`Mg-supplemented diet' (21.6 mmol Mgad) vs`unsupplemented diet (placebo)' (11.3 mmol Mgad)) for 28 d on biochemical markers of bone turnover and on blood pressure in healthy young adult females.
The trial was designed in two periods, each of 28 d, in which the Mg intakes were 11.3 mmol Mgad (self-selected Mg intake placebo) or 21.6 mmol Mgad (self-selected Mg intake 10.3 mmol Mg supplement). Subjects were randomly assigned to the unsupplemented (placebo) or Mgsupplemented diet regimens for 28 d followed by crossover to the alternative dietary regimen for a further 28 d. During the 28 d experimental periods, each subject received, in addition to their usual diet, either 10 mmol elemental Mgad, as Mg(OH) 2 (`Milk of Magnesia Tablets' SmithKline Beecham, Dun Laoghire, Co. Dublin, Ireland) in two equal doses of 5 mmol Mg each, morning and evening, so as to maximise absorption, or matching placebos also taken morning and evening. Subjects were instructed to collect fasting ®rst void urine samples between 7 ± 9 am for the last 3 d of each treatment period and for 3 d during the week immediately preceding the trial (baseline). Four day estimated diet records for each individual were also obtained over the last 4 d of each treatment period and over 4 d during the baseline week immediately preceding the trial. In addition, after an overnight fast, a blood sample (10 ml) was taken at 9 am on the morning of the 27 d of each dietary period and during the baseline week. Blood pressure was measured at 9 am on the morning of the 28 d of each dietary period and during the baseline week.
Dietary analysis
Nutrient intakes were estimated from 4 d estimated diet record data using the McCance and Widdowson's, The Composition of Foods (Paul & Southgate, 1978 database and updated versions) (Microdiet, Salford, Greater Manchester, UK).
Blood pressure measurements
Blood pressure (systolic and diastolic) were measured three times in succession in the seated position after the subjects sat quietly for at least 5 min in the morning, using a sphygmomanometer.
Collection and preparation of samples Subjects were supplied with suitable collection containers for urine samples and asked to collect fasting ®rst void morning urine samples between 7 ± 9 am each day for the last three consecutive days of each dietary period and for 3 d during the week immediately preceding the trial (baseline). Portions of urine were stored at 720 C from the morning of collection until required for analysis. Blood was collected by venepuncture into vacutainer tubes containing either no additive, EDTA or lithium heparin. Blood samples collected in vacutainer tubes with no additive and with lithium heparin were processed to serum and plasma, respectively, which were immediately stored at 770 C until required. Whole blood samples from vacutainer tubes with EDTA were used on the day of collection for determination of erythrocytes count, haemoglobin (Hb) concentration and haematocrit using a semi-automated haematology analyser (Sysmex TM F-500, TOA Medical Electronics Co. Ltd, Kobe, Japan).
Experimental techniques
Urinary pyridinoline and deoxypyridinoline. Pyridinoline and deoxypyridinoline in each of the daily urine samples from an individual collected over three consecutive days were determined by an HPLC method as described previously by Ginty et al (1998) . The mean content of the pyridinium crosslinks in the three urine collections was used to represent the individuals excretion in that dietary period.
Urinary creatinine. Fresh daily urine samples were analysed in duplicate by a colorimetric procedure using a Dietary Mg supplementation and bone biomarkers, blood pressure L Doyle et al diagnostic kit (Catalogue No. 124, 192 ; Boehringer Mannheim GmbH, Mannheim, Germany). The intra-and interassay CV were 3.4 and 6.3%, respectively.
Urinary and serum calcium and magnesium. Ca and Mg were analysed in duplicate in urine and serum samples by atomic absorption spectrophotometry as described previously by Ginty et al (1998) .
Serum osteocalcin, bone-speci®c alkaline phosphatase and parathyroid hormone. Serum bone-speci®c alkaline phosphatase (EC 3.1.3.1) and serum osteocalcin were measured using ELISA as described previously by Ginty et al (1998) . Serum parathyroid hormone (PTH) levels were measured using an ELISA (Immunodiagnostic systems Ltd, Tyne & Wear, UK). The intra-assay CV was 3.8%. Interassay variation for serum PTH was avoided by analysing all samples from an individual in the same run.
Erythrocyte Mg content. Mg content of erythrocytes was determined by an indirect method as described by Deuster et al (1987) . This involved measurement of Mg in plasma and whole blood after the erythrocytes in whole blood had been lysed with 2 M-HNO 3 . Mg content of erythrocytes was expressed as mgag Hb, nga10 6 erythrocytes, and mmolal. The intra-assay CV was 3.4%. There was no interassay variation as all samples from an individual were analysed in the same run.
Statistical analysis
Data are presented as means with their standard deviations and data for all variables were normally distributed and allowed for parametric tests of signi®cance. Comparison of means for nutrient intakes during unsupplemented (placebo) and Mg-supplemented periods were made using paired Student's t-tests. Changes in the different biochemical indices during the placebo and Mg-supplemented periods were analysed by the appropriate analysis for a 262 crossover trial with continuous data as described by Jones & Kenward (1989) in which two-sample t-tests are used to test hypotheses about direct treatments effects (namely, Mg supplementation) and carry-over effects.
Where signi®cant carry-over effects were observed, the treatment difference obtained in the ®rst period of the crossover study was used as an estimate of the true treatment difference, as these data are free of carry-over effects. The treatment differences were tested by unpaired Student's t-tests of those subjects on placebo versus those on Mg supplements.
Results
Mean dietary Mg intake was estimated to be 11 mmolad during the baseline period. Dietary Mg intakes, excluding the contribution from Mg supplementation, were similar during the unsupplemented (placebo) and Mg-supplemented dietary periods (Table 2) . Similarly, there were no signi®cant differences in the dietary intakes of energy, protein, ®bre, Ca, P or K between the placebo and Mgsupplemented dietary periods ( Table 2) .
The effects of increasing Mg intake from 11 mmolad to 22 mmolad for 28 d on erythrocyte Mg content is shown in Table 3 . Due to signi®cant carry-over effects evident in erythrocyte Mg contents when expressed both as ng Mga10 6 cells and mmol Mgal, analysis of the data for a direct treatment effect (namely, Mg supplementation) in the whole group between the two dietary periods was not possible.
While there was no signi®cant difference in the erythrocyte Mg content expressed as mg Mgag Hb between those on the placebo or Mg supplements during the ®rst experimental period of the study, erythrocyte Mg content expressed as both ng Mga10 6 cells and mmol Mgal was signi®cantly higher (P`0.05) in the group which received the Mg supplements.
The effects of Mg supplementation on serum and urinary biochemical variables and on blood pressure are shown in Table 4 . Urinary creatinine (Cr) concentration, urinary CaaCr and NaaCr and serum Ca, Mg and PTH concentrations were unaffected by dietary Mg intake.
Urinary excretion of MgaCr increased signi®cantly by $ 36% (P`0.001) when subjects were switched from the unsupplemented to Mg-supplemented diet. There were no signi®cant differences in urinary PyraCr to DpyraCr excretion when subjects were switched from the unsupplemented to Mg-supplemented diet. Similarly, serum levels of biochemical markers of bone formation (serum bone-speci®c alkaline phosphatase or serum osteocalcin) were unaffected by dietary Mg intake.
There were no signi®cant differences in systolic or diastolic blood pressure when subjects were switched from the unsupplemented to Mg-supplemented diet.
Discussion
The average habitual dietary intake of Mg in the young adult females in the present study was about 11 mmolad which is considerably lower than some recent recommendations for dietary intake of Mg for this group, for example 310 mg (12.8 mmol)ad (Institute of Medicine, 1997) or 360 mg (14.8 mmol)ad (Durlach & Mareschi, 1991) . This low Mg intake is in agreement with similar reports in other European countries and in the US which show that many young adult females have Mg intakes below the recommended levels (Gregory et al, 1990; Van Dokkum, 1995; Cleveland et al, 1996; Institute of Medicine, 1997) .
Regulation of urinary excretion of Mg is the principal mechanism controlling total body Mg and there is a strong positive correlation between the intestinal absorption and urinary excretion of Mg over the normal range of human intake (Djurhuus et al, 1995) . In this present study, urinary excretion of Mg was signi®cantly increased during the Mg supplementation period, indicating a good rate of absorption from the supplement used (Mg(OH) 2 ). Similar increases in urinary Mg have been reported in other studies that have used Mg(OH) 2 as the source of supplemental Mg (Stendig-Lindberg, 1991; Stendig-Lindberg et al, 1993; Itoh et al, 1997) .
Despite the relatively low Mg intakes at baseline, serum Mg concentration was within the acceptable range (0.75 ± 0.95 mmolal, Elin, 1987) . Furthermore, supplementation of the usual diet with additional Mg ( $ 10 mmolad) for a 28 d period had no signi®cant effect on serum Mg concentration. This is in agreement with the ®ndings of other studies which show that serum Mg in healthy subjects was unaffected by Mg supplementation (Zemel et al, 1990; Geleijnse et al, 1994; Plum-Wirell et al, 1994; Witteman et al, 1994) , con®rming that serum Mg concentration is tightly regulated, even when Mg intake is higher than normal.
Erythrocyte Mg content at baseline, expressed as mgag Hb, nga10 6 cells and as mmolal was also within the normal range (Lukaski et al, 1983; Deuster et al, 1987) . Erythrocyte Mg content, expressed as nga10 6 cells and as mmolal, but not mgag Hb, was signi®cantly increased by Mg supplementation for 28 d. This accumulation of Mg in erythrocytes is in agreement with other studies that found increases in erythrocyte Mg content with Mg supplementation (Motoyama et al, 1989; Golf et al, 1990; Borella et al, 1993) . Increases in Mg in both lymphocytes and muscle biopsies have also been documented after Mg a Direct treatment effect (namely, Mg supplementation) was analysed for each biochemical index by two sample t-tests of within group differences after testing for carry-over effects. No signi®cant carry-over effects were found for any of the biochemical indices.
Dietary Mg supplementation and bone biomarkers, blood pressure L Doyle et al supplementation (Sjogren et al, 1988; Facchinetti et al, 1989) , suggesting that Mg is rapidly removed from the intravascular space towards intracellular stores (Borrela et al, 1993) . Oral Mg supplementation for 28 d had no effect on either systolic or diastolic blood pressure in the young adult females in this present study. This is in agreement with other studies of the effect of Mg supplementation on blood pressure in normotensive individuals. Haga (1992) evaluated the antihypertensive effect of oral Mg supplementation, with 600 mg (24.7 mmol) Mgad, as MgO, for two weeks, in 17 untreated, uncomplicated mild-to-moderate essential hypertensives and eight age-matched normotensive controls. While, Mg supplementation elicited a signi®cant fall in mean blood pressure in the essential hypertensives, blood pressure in the normotensives was unaltered. A similar lack of blood pressure-lowering effect with Mg supplementation has been reported in a doubleblind, placebo controlled study of normotensive adults with a mean usual Mg intake of 10.7 mmolad who were supplemented with 15 mmol Mgad for six months (Trials of Hypertension Prevention Collaborative Research Group, 1992; Yamamoto et al, 1995) . More recently, Sacks et al (1998) studied three hundred normotensive women (mean age, 39 y), whose reported intakes of Mg, Ca, and K were 9.8, 15.9 and 62 mmolad, and received daily supplements of either 40 mmol K, 30 mmol Ca, 14 mmol Mg, all three minerals together or placebos for 16 weeks. The mean differences of the changes in systolic and diastolic blood pressures between the treatment and placebo groups were signi®cant for K, but not for Ca or Mg. Therefore, the ®ndings of this present study would suggest that increasing Mg intake in young adult normotensive females above the usual dietary intake, which is currently below recommended levels, does not lower systolic or diastolic blood pressure.
The ®ndings of this present study showed that oral Mg supplementation with 10 mmolad of Mg for 28 d had no effect on biochemical markers of either bone resorption (urinary pyridinium crosslinks of collagen) or bone formation (serum osteocalcin and serum bone-speci®c alkaline phosphatase) in healthy young adult females. Similarly, despite their suggestion that Mg may be affecting osteoblastic function and therefore, bone remodelling, StendigLindberg et al (1993) found that serum alkaline phosphatase was unaffected by Mg supplementation (750 mg (30.9 mmol)ad for the ®rst six months followed by 250 mg (10.3 mmol)ad) in their 2 y controlled study of osteoporotic women. However, it is unclear whether the reported values refer to the activity of total alkaline phosphatase or the bone-isoform of alkaline phosphatase which is a more sensitive and speci®c marker of bone formation (Delmas, 1992) .
The ®ndings of this present study contrast with those of Dimai et al (1998) who recently reported that oral supplementation of 12 healthy young males, aged 27 ± 36 y, with an additional 15 mmol of Mgad for 30 d reduced serum levels of osteocalcin and procollagen peptide (biochemical markers of bone formation) and serum type I collagen telopeptide (a biochemical marker of bone resorption), as compared to levels in a control group of 12 unsupplemented males. The authors suggest that daily oral Mg supplementation may suppress the rate of bone turnover in normal non-Mg-de®cient individuals. However, the average habitual dietary intake of Mg in the males was 12.8 mmolad, which is below the US RDA for Mg (16.5 mmolad, Institute of Medicine, 1997) .
The reduction in the rates of bone formation and bone resorption seen as early as day 5 in the study of Dimai et al (1998) would suggest that Mg supplementation, in some way, uncoupled these two processes. Usually bone formation, although coupled to resorption, is separated in time by approximately 6 ± 7 weeks (Eriksen et al, 1984) , and therefore a reduction in both these processes within 5 d of beginning Mg supplementation seems unusual. While concomitant reductions in both osteoblastic and osteoclastic activity have been reported in rats due to Mg de®ciency (Jones et al, 1980; Creedon et al, 1998) , there is no supporting evidence in the literature, either in humans or in experimental animals, of a concomitant reduction in the rates of bone formation and bone resorption due to supplementation with a nutritional level of Mg. Limitations of the study of Dimai et al (1998) included relatively low subject numbers and it was not of a randomised crossover design.
The lack of effect of Mg supplementation on the biochemical markers of bone turnover in this present study is likely to be due to the lack of effect of increased Mg intake on serum PTH levels and, consequently, no stimulus for a change in the rate of osteoclastic bone resorption. Therefore, these ®ndings would suggest that increasing Mg intake in young adult females above the usual dietary intake, which is currently below recommended levels, does not alter the rate of bone turnover. Furthermore, as the rate of bone turnover has been associated with bone mass, and has also been shown to be an independent predictor of fracture in later life (Melton et al, 1997) , increasing Mg intake in these females above the usual dietary intake, does not lower risk of fracture in later life.
Conclusions
The ®ndings of this present study suggest that increasing Mg intake in healthy young females above the usual dietary intake, which is currently below recommended levels, does not in¯uence blood pressure or the rate of bone turnover. Furthermore, while it is acknowledged that the study was of relatively short duration, it does not lend support to the suggestion that habitually low intakes of Mg result in abnormal Mg metabolism and are associated with aetiologic factors in various metabolic diseases including hypertension and osteoporosis (Rude, 1998) . However, the de®nition of habitually low intakes of Mg' in this present study relates to a usual level of Mg intake that was $ 86% of the new US RDA and therefore, the possibility that lower habitual Mg intakes may be associated with aetiologic factors in hypertension and osteoporosis cannot be dismissed.
